GHRP-6 is a synthetic six-amino-acid peptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It came out of work by American endocrinologist Cyril Bowers, who noticed in the early 1980s that chemical analogs of enkephalin amide unexpectedly triggered growth hormone release in pituitary cell cultures (Berlanga-Acosta et al., 2017, Clin Med Insights). It was the first of the growth hormone releasing peptides (GHRPs) and the template for the ones that followed, including GHRP-2, hexarelin, and ipamorelin.
When GHRP-6 was made, nobody knew what receptor it hit. That receptor, the growth hormone secretagogue receptor type 1a (GHS-R1a), was characterized as the binding site for these synthetic compounds first. Its natural ligand turned up later: ghrelin, a stomach-derived hormone identified by Kojima and colleagues in 1999 (Casanueva et al., 2008, PNAS). So GHRP-6 is, in effect, a synthetic ghrelin mimic that predates the discovery of ghrelin itself.
How it works
GHRP-6 binds and activates GHS-R1a on the pituitary and in the hypothalamus, prompting a pulse of growth hormone. It works partly through the pituitary directly and partly by acting on hypothalamic GHRH neurons, and the two routes reinforce each other. Because GHS-R1a is the ghrelin receptor, GHRP-6 also drives ghrelin-type effects, most noticeably strong appetite stimulation through neuropeptide Y and AgRP neurons in the arcuate nucleus.
There is a second receptor in the picture. GHRP-6 also binds the scavenger receptor CD36, and this is where a lot of its non-growth-hormone research sits. In animal models, CD36 engagement has been linked to prosurvival signaling such as the PI3K/AKT pathway (Berlanga-Acosta et al., 2017).
What the research shows
The pituitary effect is well established across species. GHRP-6 releases growth hormone in a dose-dependent way, and that includes early human work: intravenous GHRP-6 raised GH in healthy volunteers and was tolerated in a dose-escalation trial. Beyond those early-phase pharmacology studies, sustained clinical development in humans has been thin and, in the words of one review, "erratic and irregular."
Most of the interesting findings are preclinical. In a pig model of myocardial infarction, GHRP-6 reportedly rescued a large share of the at-risk ischemic tissue and reduced oxidative stress markers (Berlanga-Acosta et al., 2017). More recent animal work has looked at protection against doxorubicin-induced cardiac damage (Vázquez-Blomquist et al., 2024, Front Pharmacol). These are cell-culture and animal results. They point to possible cardioprotective and cytoprotective uses, but they are not a substitute for controlled human trials, which for these endpoints do not exist in any mature form.
Regulatory and doping status
GHRP-6 is not approved by the FDA, or by other major regulators, for any human indication. It is sold as a research chemical. The World Anti-Doping Agency prohibits it under category S2 (peptide hormones, growth factors, related substances and mimetics), in and out of competition, and its metabolites can be detected in urine for days after use (WADA Prohibited List, S2). Any athlete subject to anti-doping rules should treat it as banned.
The buyer-quality angle
Because GHRP-6 is sold for research use only and not as a regulated medicine, what is in the vial is not guaranteed by any health authority. Identity and purity vary between suppliers. If you are evaluating a product, the meaningful checks are third-party analytical data: a recent certificate of analysis with mass-spec identity confirmation and an HPLC purity figure tied to the specific lot. peptideone aggregates independent vendor ratings and testing signals rather than running its own assays, so cross-reference any single COA against those external sources.
Nothing here is medical, dosing, or efficacy advice. GHRP-6 is not approved for human consumption, and the bulk of the evidence beyond basic growth hormone pharmacology remains animal and laboratory data.